- Home
- About
- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- IgAN
- Events
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefR
- Radiology Toolkit
- On Demand Webinars
- Infographics
- Podcasts
- Videos
- Request a Presentation
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Kidney Disease in Native Americans & Alaskan Natives
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Kidney Disease in Native Americans & Alaskan Natives
Background
More than 5.6 million Native American and Alaskan Natives currently live in the US and comprise 1.8% of the population1. Federally recognized tribes are provided comprehensive primary health care and disease prevention through the U.S. Department of Health and Human Services Indian Health Services (IHS).2,3 IHS provides care for approximately 2.8 million American Indians and Alaskan Natives; however about 20% of American Indians and Alaskan Natives under 65 years of age are uninsured.2,3 IHS program focusing on diabetes and kidney health decreased diabetes related kidney failure in Native Americans by 54% between 1996-2013.4,5,6 However, Native Americans and Alaskan Natives are still twice as likely to be diagnosed with kidney disease compared to non-Hispanic whites.7 Studies have shown high rates of early kidney disease among non-diabetic patients as well.8
Did You Know?
Studies have identified a higher occurrence of mesangial proliferative glomerulonephritis; predominantly IgA in non-diabetic American Indians.9 A study looking at renal biopsy specimens of 166 patients found a high proportion (68%) with mesangial proliferative glomerulonephritis, which was much greater than those seen in a biopsy series of non-Native Americans (23.5%).10
Why Attend This Webinar?
This webinar discussion featuring Dr. Ashar Luqman will discuss the prevalence of various common and rare kidney diseases and comorbidities among the Native American population.
What You Will Learn
- Prevalence of CKD, comorbidities, and mortality as it relates to the Native American and Alaskan Native population.
- Common health insurance coverage and access to care issues among American Indians and Alaska Natives.
- How IgA Nephropathy affects patients of Native American and Alaskan Native population.
References
- Shah, V.O., Parker, T., de Sosa, G.R. et al. Chronic kidney disease in American Indians and Alaska Natives. Nat Rev Nephrol 2024; 20: 487–488. https://doi.org/10.1038/s41581-024-00859-5
- Indian Health Services Health Equity Report 2024. https://www.ihs.gov/sites/newsroom/themes/responsive2017/display_objects/documents/factsheets/IHS_Health_Equity_Report_FactSheet_2024.pdf
- ASPE Office of Health Policy – Issue Brief. Health Insurance Coverage and Access to Care among American Indians and Alaska Natives: Recent Trends and Key Challenges. June 2024.
- Special Diabetes Program for Indians 2020 Report to Congress: Changing the Course of Diabetes: Charting Remarkable Progress [Internet]. Rockville (MD): Indian Health Service (US); 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK571291/
- National Kidney Foundation. Kidney Disease: Fact Sheet. https://www.kidney.org/about/kidney-disease-fact-sheet
- CDC. Vital signs: Native American with Diabetes. Vital Signs: Native Americans with Diabetes | CDC Archive.
- OMH. Diabetes and American Indians/Alaskan Natives. 3/1/2021
- Narva, Andrew S. The spectrum of kidney disease in American Indians. Kidney International 2003; 63s83.
- Shah VO, et al. Epidemic of Diabetic and Nondiabetic Renal Disease among the Zuni Indians: The Zuni Kidney Project. JASN 2003.
- Hoy WE. Mesangial Proliferative Glomerulonephritis in Southwestern American Indians. AJKD 1993;21:486-96.
Speaker
Ashar Luqman, MD
Dr. Ashar Luqman, is a Board Certified in Internal Medicine and Nephrology. He graduated with a Doctor of Medicine degree from Allama Iqbal Medical College.his medical education, Dr. Luqman pursued further specialization in Nephrology by completing a Fellowship at the University of Tennessee Health Science Center.
In his professional career, Dr. Luqman has gained diverse experience in Nephrology. He has worked as a Nephrologist at Renal Associates, P.C. in Dakota Dunes, where he provided specialized care to patients with kidney-related conditions. Furthermore, he has been involved in outreach clinics, extending his expertise to rural communities in Northwest Iowa and Eastern Nebraska including Native American populations. Additionally, Dr. Luqman served as the Principal Investigator at Dunes Clinical Research, LLC and is actively involved in multiple clinical trials.
Moderator
Abigail Yancey, PharmD, FCCP, BCPS
Nephrology Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Abigail Yancey, PharmD, FCCP, BCPS, is a Medical Science Liaison at Otsuka Pharmaceuticals Development & Commercialization, Inc. (OPDC). Dr Yancey earned her B.S. in Pharmacy and Doctorate in Pharmacy (PharmD) from St. Louis College of Pharmacy in St. Louis, MO. She completed a pharmacy practice residency at University Hospital in Cincinnati, Ohio and a specialty residency in adult internal medicine at The Ohio State University. Prior to joining Otsuka, she spent 18-years at St. Louis College of Pharmacy as a Professor in the Department of Pharmacy Practice with a clinical practice site at SSM Health St. Mary’s Hospital. Dr Yancey was highly involved as an interdisciplinary educator for internal medicine resident physicians and a preceptor for both pharmacy students and residents. Dr Yancey is a Board Certified Pharmacotherapy Specialist (BCPS) and is a Fellow of the American College of Clinical Pharmacy (FCCP).
Dr. Ashar Luqman is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
Dr. Abigail M. Yancey is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional.
October 2024 US.CORP.X.24.00300Registration
Please Log In Or Join to Register for this Event.
Related Resources
-
Breakdown of the MEST-C Score in IgA Nephropathy
Audio/Podcast November 12, 2024This podcast provides an in-depth review of the Oxford MEST-C score, focusing on its practical application in diagnosing and prognosticating IgA Nephropathy.
-
Role of the Renal Pathologist in IgA Nephropathy
On-Demand Webinar November 6, 2024Through the lens of renal pathology, this webinar will provide insights into the histopathological features that are crucial for accurate diagnosis and risk stratification in IgA Nephropathy, highlighting the significance…
-
Kidney Transplant In Patients With IgA Nephropathy (IgAN)
Infographic October 16, 2024Learn about issues relating to kidney transplantation and IgAN.
Related Events
-
Cooking Demo: Dietary Considerations for Patients with IgA Nephropathy
January 8, 2025 from 12:00 pm to 1:00 pm
Join Today for Instant Access to all NephU Offerings.
Membership is free!
Join NephU today at no cost to register for this event and access to other premium content.
- The NephU Community is collaborating to improve care and the future outcomes for individuals with kidney disease and other related conditions.
- Quickly learn more about the topics that interest you.
- Access our library of on-demand kidney health resources
- Gain key insights from industry experts & though leaders.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.